GBIO
Generation Bio Co.5.38
-0.01-0.19%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
36.25MP/E (TTM)
-Basic EPS (TTM)
-9.37Dividend Yield
0%Recent Filings
8-K
XOMA acquires Generation Bio
XOMA Royalty completed its acquisition of Generation Bio on February 9, 2026, via tender offer accepting 70% of shares at $4.2913 cash plus CVR, followed by short-form merger making GBIO a wholly-owned subsidiary. Trading halted; board and officers cleared out. Company paid $21.5M to terminate Cambridge lease. Going private.
8-K
GBIO merger at $4.29/share + CVR
Generation Bio signed a merger deal with XOMA Royalty on December 15, 2025, for $4.2913 cash per share plus a CVR tied to net cash above $28.97 million, lease savings, IP sales, and Moderna proceeds. A tender offer starts soon, targeting February 2026 close after majority tender; holders of 15.38% shares pledged support. CVR payouts hinge on uncertain milestones.
10-Q
Q3 FY2025 results
Generation Bio narrowed Q3 losses to $5.5M from $15.3M y/y, thanks to a $25.5M gain on Seyon Lease termination that offset $8.3M operating expenses—down from $25.4M—while collaboration revenue with Moderna dipped to $1.6M from $7.6M. YTD net loss improved to $41.2M from $110.3M, with cash and equivalents plus marketable securities at $89.6M after $97.9M operating burn. August restructuring slashed 90% of workforce to pursue strategic alternatives like sale or merger. Cash lasts 12+ months, yet strategic process outcome remains uncertain.
8-K
Q3 loss narrows sharply
Generation Bio reported Q3 2025 net loss of $5.5 million, far better than $15.3 million last year, thanks to a $25.5 million gain on lease termination after paying $31.0 million to settle Waltham facility litigation in August. Cash dropped to $89.6 million from $185.2 million year-end 2024. Strategic alternatives process underway.
8-K
CEO transition announced
Generation Bio announced CEO Geoff McDonough's resignation effective October 31, 2025, amid its strategic alternatives review, with him transitioning to Board Chair under a separation deal including $700,000 cash severance, $300,000 bonus payment, and 25% equity vesting acceleration. Yalonda Howze, former Chief Legal Officer, steps in as Interim CEO and President with $575,000 base salary. Transition smooths leadership amid uncertainties.
CBIO
Crescent Biopharma, Inc.
12.92-0.29
GERN
Geron Corporation
1.34+0.01
GLTO
Galecto, Inc.
30.00-1.60
GRI
GRI Bio, Inc.
0.48+0.00
GTBP
GT Biopharma, Inc.
0.72+0.09
IMA
ImageneBio, Inc.
6.25+0.08
INAB
IN8bio, Inc.
1.50-0.10
PASG
Passage Bio, Inc.
9.45-0.60
RGBP
Regen Biopharma, Inc.
0.01-0.00
TRML
Tourmaline Bio, Inc.
47.98+47.98